BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BIO - US0905722072 - Common Stock
313.53 USD
-8.53 (-2.65%)
313.53 USD
0 (0%)
Taking everything into account, BIO scores 4 out of 10 in our fundamental rating. BIO was compared to 57 industry peers in the Life Sciences Tools & Services industry. BIO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year BIO was profitable.
- In the past year BIO had a positive cash flow from operations.
- In multiple years BIO reported negative net income over the last 5 years.
- In the past 5 years BIO always reported a positive cash flow from operatings.
1.2 Ratios
- BIO has a Return On Assets (-6.97%) which is comparable to the rest of the industry.
- BIO has a Return On Equity of -10.03%. This is comparable to the rest of the industry: BIO outperforms 52.63% of its industry peers.
- BIO has a better Return On Invested Capital (2.26%) than 61.40% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BIO is significantly below the industry average of 13.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
- The Operating Margin of BIO (10.27%) is better than 70.18% of its industry peers.
- BIO's Operating Margin has been stable in the last couple of years.
- BIO has a Gross Margin of 52.42%. This is in the better half of the industry: BIO outperforms 63.16% of its industry peers.
- BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
- BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for BIO has been reduced compared to 1 year ago.
- The number of shares outstanding for BIO has been reduced compared to 5 years ago.
- BIO has a worse debt/assets ratio than last year.
2.2 Solvency
- BIO has an Altman-Z score of 3.43. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
- BIO has a better Altman-Z score (3.43) than 66.67% of its industry peers.
- The Debt to FCF ratio of BIO is 3.57, which is a good value as it means it would take BIO, 3.57 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 3.57, BIO is in the better half of the industry, outperforming 77.19% of the companies in the same industry.
- A Debt/Equity ratio of 0.18 indicates that BIO is not too dependend on debt financing.
- BIO has a Debt to Equity ratio of 0.18. This is comparable to the rest of the industry: BIO outperforms 57.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.43 |
ROIC/WACC0.21
WACC10.7%
2.3 Liquidity
- A Current Ratio of 5.44 indicates that BIO has no problem at all paying its short term obligations.
- BIO's Current ratio of 5.44 is amongst the best of the industry. BIO outperforms 85.96% of its industry peers.
- A Quick Ratio of 3.94 indicates that BIO has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 3.94, BIO is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
- The earnings per share for BIO have decreased by -1.90% in the last year.
- The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
- BIO shows a decrease in Revenue. In the last year, the revenue decreased by -0.88%.
- The Revenue has been growing slightly by 2.11% on average over the past years.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
- Based on estimates for the next years, BIO will show a decrease in Earnings Per Share. The EPS will decrease by -2.66% on average per year.
- BIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.26% yearly.
EPS Next Y-2.19%
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
EPS Next 5Y-2.66%
Revenue Next Year0.15%
Revenue Next 2Y1.2%
Revenue Next 3Y1.9%
Revenue Next 5Y1.26%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 30.41, the valuation of BIO can be described as expensive.
- Based on the Price/Earnings ratio, BIO is valued a bit cheaper than 75.44% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.38, BIO is valued at the same level.
- Based on the Price/Forward Earnings ratio of 30.44, the valuation of BIO can be described as expensive.
- Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than 70.18% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.29, BIO is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.41 | ||
| Fwd PE | 30.44 |
4.2 Price Multiples
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of BIO indicates a rather cheap valuation: BIO is cheaper than 82.46% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.11 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.88
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
5. Dividend
5.1 Amount
- No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
313.53
-8.53 (-2.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)02-11 2026-02-11/amc
Inst Owners92.92%
Inst Owner Change0.07%
Ins Owners8.18%
Ins Owner Change0%
Market Cap8.46B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target362.1 (15.49%)
Short Float %4.91%
Short Ratio4.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)0%
PT rev (3m)14.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.58%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)3.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.14%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)-0.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.41 | ||
| Fwd PE | 30.44 | ||
| P/S | 3.31 | ||
| P/FCF | 25.11 | ||
| P/OCF | 17.2 | ||
| P/B | 1.26 | ||
| P/tB | 1.47 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.29%
EPS(NY)10.3
Fwd EY3.29%
FCF(TTM)12.48
FCFY3.98%
OCF(TTM)18.22
OCFY5.81%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)N/A
PEG (5Y)3.88
Graham Number240.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.43 |
F-Score5
WACC10.7%
ROIC/WACC0.21
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-2.19%
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.15%
Revenue Next 2Y1.2%
Revenue Next 3Y1.9%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.67%
EBIT Next 3Y14.51%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
Can you provide the valuation status for BIO-RAD LABORATORIES-A?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for BIO stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to decline by -2.19% in the next year.